Genetic and epigenetic analysis of the beta-2-microglobulin gene in microsatellite instable colorectal cancer
Open accessThe DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
One of the most common mechanisms of immune evasion in MSI colorectal cancers (CRCs) is loss of HLA class I expression due to mutations in B2M gene which can become a negative predictor for checkpoint blockade therapy. The aim of this study was the determination of prevalence of B2M somatic mutations in MSI CRC patients and relationship between B2M mutations and lymphocytes infiltration and other clinicopathological features as well as detection of methylation changes in B2M promoter region which can be another mechanism of immune escape. In our study, 37 MSI-H and 5 MSI-L patients were selected for screening of B2M mutational and methylation status. The characterization of patients was based on standard histopathological diagnosis and TNM classification; BRAF, KRAS mutations, tumor-infiltrating lymphocytes and peritumoral lymphoid reaction were also determined. MSI analysis was performed using fragment analysis. B2M mutations were identified by Sanger sequencing, and methylation of CpG islands in promoter region was detected by methylation-specific PCR. Heterozygous mutations in the B2M gene were detected in five MSI-H patients (13.5%), while the mutation c.45_48delTTCT was determined in four patients and mutation c.276delC was found in two patients. One of these five patients was compound heterozygote harboring both mutations. Methylation of the promoter region of the B2M gene was observed in one patient with MSI-H colorectal cancer. Detection of genetic and epigenetic changes in B2M gene could be important in personalized therapy for CRC patients as these changes may be one of the mechanisms of secondary resistance of MSI positive tumors to immunotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“genetic and epigenetic aberrations leading to defects in antigen presentation can promote primary and acquired resistance to ICB regardless of TMB (Snahnicanova et al., 2020; Sucker et al., 2014).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Snahnicanova et al., 2020
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 2×
“This hypothesis is supported by the increased accumulation of B2M mutations during and after therapy by immune checkpoint inhibitors [7, 8, 20, 21, 44].”
BackgroundType, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“These strategies include positive selection of antigens lacking cancer cells and defects in antigen presentation through defects in expression of HLA molecules or in antigen processing pathways [33, 34].”
BackgroundMutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · cited 3×
“In our study, we focused on the detection of mutational and methylation status of B2M gene as mechanisms leading to downregulation or loss of gene expression and consequently to impaired antigen presentation, immune evasion and immunotherapy resistance [21].”
BackgroundMethodClonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Microsatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456 · cited 1×
“From the clinical point of view, colorectal cancer patients with high level of MSI have favorable prognosis and lower frequency of distant metastases compared to microsatellite stable (MSS) tumors [1, 3, 4].”
Background
Cited by
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects
Wu, X., Li, T., Jiang, R., Yang, X., Guo, H., & Yang, R. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01899-4 · Cited by 223
“In patients with MSI colorectal cancer, promoter methylation at the B2M gene was observed [54].”
BackgroundResistance mechanisms to immune checkpoint inhibitors: updated insights
Alsaafeen, B. H., Ali, B. R., & Elkord, E. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02212-7 · Cited by 191
Beta2-microglobulin(B2M) in cancer immunotherapies: Biological function, resistance and remedy
Wang, H., Liu, B., & Wei, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.008 · Cited by 190
Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape
Mulet-Margalef, N., Linares, J., Badia-Ramentol, J., Jimeno, M., Sanz, C., Mozo, J. L. M., & Calon, A. (2023) · Cancers · doi:10.3390/cancers15041022 · Cited by 124
Metadata
- Authors
- Snahnicanova, Z., Kasubova, I., Kalman, M., Grendar, M., Mikolajcik, P., Gabonova, E., Laca, L., Caprnda, M., Rodrigo, L., Ciccocioppo, R., Kruzliak, P., Plank, L., & Lasabova, Z.
- Affiliations
- Martin University Hospital (SK)
- Comenius University Bratislava (SK)
- University of Verona (IT)
- Venue
- Clinical and Experimental Medicine
- Published
- 2019-12-18
- Volume
- 20
- Issue
- 1
- Pages
- 87-95
- ISSN
- 1591-8890 (ISSN-L)
- 1591-9528
- OpenAlex
- W2995284100
- Cited by
- 29
- References
- 55
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 5 · 2023: 7 · 2022: 5 · 2021: 5 · 2020: 3
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc-nd
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Clinical and Experimental Medicine (publishedVersion)
- PubMed (publishedVersion)
- Consultation of the Doctoral Thesis Database (TESEO) (Ministerio de Educación, Cultura y Deporte) (submittedVersion, cc-by-nc-nd)
- Funders
- Agentúra Ministerstva Školstva, Vedy, Výskumu a Športu SR (APVV-16-0066)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- beta2-microglobulin, microsatellite instability, colorectal cancer, immune evasion, HLA class I loss, promoter methylation, tumor-infiltrating lymphocytes, immunotherapy resistance, checkpoint blockade, compound heterozygosity
- MeSH terms
- Adult, Aged, Aged, 80 and over, beta 2-Microglobulin, Female, Humans, Male, Middle Aged, Mutation, Neoplasm Staging, Promoter Regions, Genetic, Colorectal Neoplasms, Down-Regulation, Gene Expression Regulation, Neoplastic, CpG Islands, DNA Methylation, Epigenesis, Genetic, Microsatellite Instability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetic and epigenetic analysis of the beta-2-microglobulin gene in microsatellite instable colorectal cancer. https://app.cochat.ai/papers/10.1007/s10238-019-00601-7
- The paper
- Snahnicanova, Z., Kasubova, I., Kalman, M., Grendar, M., Mikolajcik, P., Gabonova, E., Laca, L., Caprnda, M., Rodrigo, L., Ciccocioppo, R., Kruzliak, P., Plank, L., & Lasabova, Z. (2020). Genetic and epigenetic analysis of the beta-2-microglobulin gene in microsatellite instable colorectal cancer. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-019-00601-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.